Skip to main content
SpringerLink
Log in

Vom Kompetenznetz Hepatitis (HepNet) zur Deutschen Leberstiftung

From the national competence network for viral hepatitis (HepNet) emerged the German Liver Foundation (Deutsche Leberstiftung)

  • Leitthema
  • Published:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Aims and scope

Zusammenfassung

Das Kompetenznetz Hepatitis (HepNet) wurde 2002 mittels einer Förderung durch das Bundesministerium für Bildung und Forschung (BMBF) gegründet und hat in den letzten 13 Jahren die Hepatitisforschung in Deutschland maßgeblich beeinflusst. Zentren des Kompetenznetzes waren an zahlreichen Therapiezulassungsstudien beteiligt. Im HepNet Study-House wurden und werden wegweisende Investigator initiierte Studien zum Beispiel zur Therapieoptimierung, zur akuten Hepatitis C und zur chronischen Hepatitis D (delta) durchgeführt. Mit Gründung der Deutschen Leberstiftung wurde eine Verstetigung des Kompetenznetzes Hepatitis erreicht. Aktuell ist die Deutsche Leberstiftung auch externer Kooperationspartner des Deutschen Zentrums für Infektionsforschung (DZIF). Das HepNet Study-House liefert die Studienplattform für die Hepatitisstudien des DZIF.

Abstract

The competence network for viral hepatitis (HepNet) was founded in 2002 with funding from the German government and has influenced the research on viral hepatitis in Germany. HepNet collaborator sites have been involved in numerous national and international investigator-initiated, as well as industry-sponsored, phase 1–3 studies. Within the HepNet Study-House, many groundbreaking investor-initiated trials have been completed and are still ongoing. For example, the acute hepatitis C trials and trials on chronic hepatitis D (delta), which led to therapy optimization. Continuation of the competence network on viral hepatitis has been achieved by the foundation of the German Liver Foundation, which has been an external cooperation partner of the German Center for Infection Research (DZIF) for two years. The well-established HepNet Study-House acts here as the clinical trial platform for all DZIF hepatitis trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Cornberg M et al (2011) Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection – The German Guideline. Z Gastroenterol 49(7):871–930

    Article  CAS  PubMed  Google Scholar 

  2. Wedemeyer H et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364(4):322–331

    Article  CAS  PubMed  Google Scholar 

  3. Yurdaydin C et al (2012) Pegylated-interferon-a-2a plus Tenofovir or placebo for the treatment of hepatitis delta: first results of the HIDIT-2 study. Hepatology 56(203a):202a

    Google Scholar 

  4. Jaeckel E et al (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345(20):1452–1457

    Article  CAS  PubMed  Google Scholar 

  5. Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43(2):250–256

    Article  CAS  PubMed  Google Scholar 

  6. Deterding K et al (2013) Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13(6):497–506

    Article  PubMed  Google Scholar 

  7. Sarrazin C et al (2010) Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol 48(2):289–351

    Article  CAS  PubMed  Google Scholar 

  8. Dintsios CM et al (2010) Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 22(3):278–288

    Article  PubMed  Google Scholar 

  9. Vogel M et al (2009) Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large german networks on the study of acute HCV infection. Clin Infect Dis 49(2):317–319. doi:10.1086/600058

    Article  PubMed  Google Scholar 

  10. Deterding K et al (2009) The german hep-net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 47(6):531–540

    Article  CAS  PubMed  Google Scholar 

  11. Wiegand J et al (2007) Fate and function of hepatitis-C-virus-specific T‑cells during peginterferon-alpha 2b therapy for acute hepatitis C. Antivir Ther (Lond) 12(3):303–316

    CAS  Google Scholar 

  12. Wiegand J et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43(2):250–256

    Article  CAS  PubMed  Google Scholar 

  13. Wiegand J et al (2004) Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 40(1):98–107

    Article  CAS  PubMed  Google Scholar 

  14. Friedrich-Rust M et al (2012) Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. Hepatology 56:840a

    Article  Google Scholar 

  15. Wiese M et al (2014) Evaluation of liver disease progression in the german hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 59(1):49–57

    Article  CAS  PubMed  Google Scholar 

  16. Heidrich B et al (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60(1):87–97

    Article  CAS  PubMed  Google Scholar 

  17. Sarrazin C et al (2011) Improved responses to Pegylated interferon alfa-2b and Ribavirin by individualizing treatment for 24–72 weeks. Gastroenterology 141(5):1656–1664

    Article  CAS  PubMed  Google Scholar 

  18. Berg T et al (2009) Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1‑infected patients. Hepatology 50(2):369–377

    Article  CAS  PubMed  Google Scholar 

  19. Heidrich B et al (2014) reatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One 9(10):p. e108751

    Article  Google Scholar 

  20. von Wagner M et al (2008) Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology 48(5):1404–1411

    Article  Google Scholar 

  21. Manns MP, von Hahn T (2013) Novel therapies for hepatitis C – one pill fits all? Nat Rev Drug Discov 12(8):595–610

    Article  CAS  PubMed  Google Scholar 

  22. Manns MP, Cornberg M (2013) Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 13(5):378–379

    Article  PubMed  Google Scholar 

  23. Wedemeyer H et al (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 21(Suppl 1):60–89

    Article  PubMed  Google Scholar 

  24. Razavi H et al (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 21(Suppl 1):34–59

    Article  PubMed  Google Scholar 

Download references

Danksagung

Die erfolgreiche Arbeit des Kompetenznetzes Hepatitis und der Deutschen Leberstiftung ist nur dank des Engagements der Mitarbeiter der Geschäftsstelle der Deutschen Leberstiftung, des Vorstandes, des Stiftungsrates und des Kuratoriums der Deutschen Leberstiftung möglich. Außerdem gilt unser Dank den Mitarbeitern, Mitgliedern, dem erweiterten Vorstand und dem Wissenschaftlichen Beirat des HepNet, die von 2002 bis 2011 das Kompetenznetz Hepatitis aufgebaut und koordiniert haben.

Weitere Informationen: www.kompetenznetz-hepatitis.de; www.deutsche-leberstiftung.de

Author information

Authors and Affiliations

  1. Deutsche Leberstiftung, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    S. Hardtke, B. Wiebner &  M. P. Manns

Authors
  1. S. Hardtke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Wiebner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. P. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. P. Manns.

Ethics declarations

Interessenkonflikt

S. Hardtke und B. Wiebner geben an, dass kein Interessenkonflikt besteht. M.P. Manns: Beratertätigkeit, Forschungsunterstützung, Studienteilnahme oder Vortragshonorare von: AbbVie, Achillion, Biotest, Bristol-Myers-Squibb, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Pharma, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen, Merck/MSD, Novartis, Roche.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hardtke, S., Wiebner, B. & Manns, M.P. Vom Kompetenznetz Hepatitis (HepNet) zur Deutschen Leberstiftung. Bundesgesundheitsbl. 59, 482–488 (2016). https://doi.org/10.1007/s00103-016-2319-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00103-016-2319-6

Schlüsselwörter

Keywords

Search

Navigation